drugset / Trial / NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
Timeline
- Start
- 2017-12-01
- Primary completion
- 2022-09-13
- Completion
- 2022-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDX-1140 | Monoclonal antibody | — | — |
| Background | CDX-301 | Protein / enzyme biologic | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
Indications
MALT lymphoma
Waldenstrom macroglobulinemia
breast cancer
cholangiocarcinoma
chronic lymphocytic leukemia/small lymphocytic lymphoma
colorectal cancer
diffuse large B-cell lymphoma
esophageal cancer
fallopian tube cancer
follicular lymphoma
gastric cancer
head and neck cancer
mantle cell lymphoma
melanoma
non-small cell lung carcinoma
ovarian cancer
pancreatic adenocarcinoma
primary peritoneal carcinoma
renal cell carcinoma
urothelial carcinoma